Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Delenex, Cell Medica deal

    Delenex Therapeutics AG, Zurich, Switzerland Cell Medica Ltd., London, U.K. Business: Autoimmune, Cancer Cell Medica acquired Delenex. Cell Medica plans to use Delenexs PENTRA antibody fragment platform to develop next-…

    Published on 7/18/2016
  • Eleven Biotherapeutics, Roche deal

    Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Ophthalmic Eleven will receive a $22.5 million milestone payment from Roche under a June deal …

    Published on 7/18/2016
  • Eli Lilly, Regen BioPharma deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Regen BioPharma Inc. (OTCQB:RGBP), La Mesa, Calif. Business: High throughput screening Regen and Eli Lilly partnered to evaluate Lilly compounds with Regens nuclear …

    Published on 7/18/2016
  • Emulate, Seres Therapeutics deal

    Emulate Inc., Cambridge, Mass. Seres Therapeutics Inc. (NASDAQ:MCRB), Cambridge, Mass. Business: Gastrointestinal Microbiome company Seres and Emulate partnered to use Emulates Intestine-Chip platform to identify …

    Published on 7/18/2016
  • Evelo, Epiva deal

    Evelo Biosciences Inc., Cambridge, Mass. Epiva BioSciences, Cambridge, Mass. Business: Autoimmune, Cancer, Inflammation Flagship Ventures merged its portfolio companies Evelo and Epiva. The merged entity, which will …

    Published on 7/18/2016
  • FibroGen, AstraZeneca deal

    FibroGen Inc. (NASDAQ:FGEN), San Francisco, Calif. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Hematology FibroGen said it received a scheduled $62 million license payment from AstraZeneca under a 2013 …

    Published on 7/18/2016
  • Five Prime, University of Minnesota deal

    Five Prime Therapeutics Inc. (NASDAQ:FPRX), South San Francisco, Calif. University of Minnesota, Minneapolis, Minn. Business: Gene/Cell therapy Five Prime and the university partnered to generate hematopoietic stem …

    Published on 7/18/2016
  • Paion, Cosmo deal

    Paion AG (Xetra:PA8), Aachen, Germany Cosmo Pharmaceuticals N.V. (SIX:COPN), Dublin, Ireland Business: Neurology Paion granted Cosmos Cosmo Technologies Ltd. subsidiary exclusive U.S. rights to develop and commercialize…

    Published on 7/18/2016
  • RedoxTherapies, Juno Therapeutics deal

    RedoxTherapies Inc., Boston, Mass. Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Business: Cancer Juno acquired fellow cancer company RedoxTherapies. RedoxTherapies will receive $10 million in cash up front and …

    Published on 7/18/2016
  • Sagent Pharmaceuticals, Nichi-Iko deal

    Sagent Pharmaceuticals Inc. (NASDAQ:SGNT), Schaumburg, Ill. Nichi-Iko Pharmaceutical Co. Ltd. (Tokyo:4541), Toyama, Japan Business: Generics Nichi-Iko will acquire generics company Sagent for $21.75 per share in cash in…

    Published on 7/18/2016
  • Selexis, Progenics deal

    Selexis S.A., Geneva, Switzerland Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Tarrytown, N.Y. Business: Cancer Selexis granted Progenics rights to use Selexis CHO-M Cell Line and the SUREtechnology platform to develop…

    Published on 7/18/2016
  • Serendex, Savara deal

    Serendex Pharmaceuticals A/S (OSE:SENDEX), Horsholm, Denmark Savara Pharmaceuticals, Austin, Texas Business: Pulmonary Savara acquired fellow pulmonary company Serendex in a stock deal. Savara will gain Molgradex, a …

    Published on 7/18/2016
  • Sorrento, Servier deal

    Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Servier, Neuilly-sur-Seine, France Business: Cancer Sorrento granted Servier exclusive, worldwide rights to STI-A1110, a preclinical mAb against PD-1. Sorrento…

    Published on 7/18/2016
  • Sosei, AstraZeneca deal

    Sosei Group Corp. (Tokyo:4565), Tokyo, Japan AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Cancer Soseis Heptares Therapeutics subsidiary received a $10 million milestone payment from AstraZeneca under a …

    Published on 7/18/2016
  • Weizmann Institute of Science, TxCell deal

    Weizmann Institute of Science, Rehovot, Israel TxCell S.A. (Euronext:TXCL), Valbonne, France Business: Autoimmune, Inflammation TxCell exercised an option under a 2015 deal for exclusive, worldwide rights to a chimeric …

    Published on 7/18/2016
  • X-Chem, Bayer deal

    X-Chem Inc., Waltham, Mass. Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Pharmaceuticals X-Chem and Bayer expanded their 2012 drug discovery deal to include multiple undisclosed therapeutic areas and target …

    Published on 7/18/2016
  • Xbiotech, MegaPharm deal

    XBiotech Inc. (NASDAQ:XBIT), Austin, Texas MegaPharm Ltd., Raanana, Israel Business: Cancer XBiotech granted MegaPharm rights to commercialize Xilonix in Israel to treat advanced colorectal cancer. XBiotech will receive…

    Published on 7/18/2016
  • Zymeworks, BC Cancer Agency, University of Victoria deal

    Zymeworks Inc., Vancouver, B.C. BC Cancer Agency, Vancouver, B.C. University of Victoria, Victoria, B.C. Business: Cancer Zymeworks partnered with University of Victoria and BC Cancer Agency to develop cytokine and …

    Published on 7/18/2016
  • AC Immune, Genentech, Roche deal

    AC Immune S.A., Lausanne, Switzerland Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Neurology AC Immune will receive a CHF14 million ($14.4 million) milestone …

    Published on 7/11/2016
  • Advanced Cell Diagnostics, Bio-Techne deal

    Advanced Cell Diagnostics Inc., Hayward, Calif. Bio-Techne Corp. (NASDAQ:TECH), Minneapolis, Minn. Business: Supply/Service Research supplier Bio-Techne will acquire Advanced Cell Diagnostics. Advanced Cell Diagnostics …

    Published on 7/11/2016
  • Amgen, Takeda deal

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Neurology, Cancer Takeda said it returned its Japanese rights to fulranumab (AMG 403) and trebananib (…

    Published on 7/11/2016
  • AstraZeneca, Leo Pharma deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Leo Pharma A/S, Ballerup, Denmark Business: Autoimmune, Dermatology AstraZeneca granted Leo exclusive, worldwide rights to tralokinumab (CAT-354) for dermatological …

    Published on 7/11/2016
  • AstraZeneca, Valeant Pharmaceuticals deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Laval, Quebec Business: Autoimmune The companies terminated the European portion of a deal granting Valeant…

    Published on 7/11/2016
  • Carmot, Genentech, Roche deal

    Carmot Therapeutics Inc., San Francisco, Calif. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Pharmaceuticals Carmot and Roches Genentech unit partnered to use …

    Published on 7/11/2016
  • Cormorant, Bristol-Myers deal

    Cormorant Pharmaceuticals AB, Stockholm, Sweden Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer Bristol-Myers Squibb acquired Cormorant for $95 million in upfront and near-term milestone payments …

    Published on 7/11/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993